Two Drugmakers Dominate Obesity Boom, Tiny Fund Holds Both
Two drugmakers lead the obesity drug surge, while a small fund owns both names at a fractional stake. This highlights...
This piece contrasts fee structures across popular index funds to help you pick the one with the lowest ongoing costs.
24,420 articlesTwo drugmakers lead the obesity drug surge, while a small fund owns both names at a fractional stake. This highlights...
A Phase 3 breakthrough unleashed a dramatic move in Cogent Biosciences. A large fund followed with a sizable stake, s...
Across software-as-a-service stocks, Wix has been a standout case of a dramatic pullback. This piece breaks down why ...
AMZY, the YieldMax AMZN Option Income Strategy ETF, uses a synthetic covered-call approach to generate monthly distri...
Two midstream ETFs compete on tax structure and cash-flow strategy. A closer look at AMLP and MLPX reveals how holdin...
As markets swing in early 2026, three actively-managed ETFs are drawing inflows for steady income and downside protec...
A new income strategy built on equal weighted dividends across 54 stocks has posted 24.7% returns over the last year ...
Two retail giants, two very different paths to trillion-dollar status. This guide breaks down the case for Walmart an...
A blended income plan aims to deliver $36,000 in annual cash flow from a $480,000 portfolio that showers income while...
Mega rounds in drones and AI-driven drug discovery signal big shifts in tech investing. This piece explains the perso...
Markets just hit fresh highs on AI optimism, but a familiar warning sign is flashing. This time-tested metric foresha...
Global markets sold off after leaders offered little concrete trade progress. Investors warn that day one of talks ma...